Articles

In a prospective trial, the VEGFR-2 small-molecule inhibitor apatinib has shown promising efficacy and safety signals. Read More ›

Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early. Read More ›

A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer. Read More ›

The antibody-drug conjugate mirvetuximab soravtansine combined with pembrolizumab has a manageable safety profile and encouraging signals of clinical activity. Read More ›

A successful antibiotic stewardship intervention can reduce the usage of fluoroquinolones for patient safety and resistance concerns in community-acquired pneumonia. Read More ›

Investigators evaluated the in vitro activity of omadacycline, a novel aminomethylcycline antibiotic, against a collection of clinical isolates resistant to other available tetracyclines. Read More ›

When considering antibiotic-prescribing guidelines in the community setting, is “one size fits all” applicable in the face of emerging extended-spectrum cephalosporin-resistant Enterobacteriaceae? Read More ›

The efficacy of omadacycline was demonstrated in Gram-positive and Gram-negative clinical isolates from 3 completed phase 3 trials involving tetracycline nonsusceptible pathogens. Read More ›

Researchers compared epidemiologic and healthcare resource utilization data on Escherichia coli community-acquired bacterial pneumonia with that of pneumococcal community-acquired bacterial pneumonia. Read More ›

Omadacycline provides significant improvement in the physical component of quality of life for adult subjects with an acute bacterial skin and skin structure infection known or suspected to be due to a Gram-positive pathogen. Read More ›